Human soluble epoxide hydrolase: Structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids

Protein Science

Volumn 15, Issue 1, 2006, Pages 58-64

  Gomez, German A ^a   Morisseau, Christophe ^b   Hammock, Bruce D ^b   Christianson, David W ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Domain swapped dimer; Epoxide hydrolase; Inhibition

Indexed keywords

14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 4 (3 ADAMANTYLUREIDO)BUTYRIC ACID; 4 (3 ADAMANTYLUREIDO)BUTYRIC ACID METHYL ESTER; 4 (3 CYCLOHEXYLUREIDO)BUTYRIC ACID; 4 (3 CYCLOHEXYLUREIDO)BUTYRIC ACID METHYL ESTER; 4 (3 CYCLOHEXYLUREIDO)ETHANOIC ACID; 4 (3 CYCLOHEXYLUREIDO)ETHANOIC ACID METHYL ESTER; 4 (3 CYCLOHEXYLUREIDO)HEPTANOIC ACID; 4 (3 CYCLOHEXYLUREIDO)HEXANOIC ACID; 4 (3 CYCLOHEXYLUREIDO)HEXANOIC ACID METHYL ESTER; CARBON; CARBOXYLIC ACID DERIVATIVE; EPOXIDE HYDROLASE; N CYCLOHEXY N' (3 PHENYL)PROPYLUREA; N CYCLOHEXY N' IODOPHENYLUREA; N,N' ADAMENTYLUREA; OXYGENASE INHIBITOR; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; CORRELATION ANALYSIS; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG PROTEIN BINDING; ENZYME INHIBITION; HYDROPHOBICITY; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTON TRANSPORT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; ARACHIDONIC ACIDS; BINDING SITES; CARBOXYLIC ACIDS; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; MICE; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOLUBILITY;

MURINAE;

EID: 29344455172     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.051720206     Document Type: Article

References (40)

1. Arand, M., Wagner, H., and Oesch, F. 1996. Asp333, Asp495, and His523 form the catalytic triad of rat soluble epoxide hydrolase. J. Biol. Chem. 271: 4223-4229.
2. Argiriadi, M.A., Morisseau, C., Hammock, B.D., and Christianson, D.W. 1999. Detoxification of environmental mutagens and carcinogens: Structure, mechanism, and evolution of liver epoxide hydrolase. Proc. Natl. Acad. Sci. 99: 10637-10642.
3. Argiriadi, M.A., Morisseau, C., Goodrow, M.H., Dowdy, D.L., Hammock, B.D., and Christianson, D.W. 2000. Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation. J. Biol. Chem. 275: 15265-15270.
4. Beetham, J.K., Tian, T., and Hammock, B.D. 1993. cDNA cloning and expression of a soluble epoxide hydrolase from human liver. Arch. Biochem. Biophys. 305: 197-201.
5. Borhan, B., Jones, A.D., Pinot, F., Grant, D.F., Kurth, M.J., and Hammock, B.D. 1995. Mechanism of soluble epoxide hydrolase. J. Biol. Chem. 270: 26923-26930.
6. Brünger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.-S., Kuszewski, J., Nilges, M., Pannu, N.S., et al. 1998. Crystallography and NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54: 905-921.
7. Campbell, W.B., Gebremedhin, D., Pratt, P.F., and Harder, D.R. 1996. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. 78: 415-423.
8. Capdevila, J.H., Falck, J.R., and Harris, R.C. 2000. Cytochrome P450 and arachidonic acid bioactivation: Molecular and functional properties of the arachidonate monooxygenase. J. Lipid Res. 41: 163-181.
9. DeLano, W.L. 2002. The PyMOL user's manual. DeLano Scientific, San Carlos, CA.
10. Esnouf, R.M. 1997. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J. Mol. Graph. Model. 15: 132-134.
11. Fang, X., Kaduce, T.L., Weintraub, N.L., Harmon, S., Teesch, L.M., Morisseau, C., Thompson, D.A., Hammock, B.D., and Spector, A.A. 2001. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. J. Biol. Chem. 276: 14867-14874.
12. Fisslthaler, B., Popp, R., Kiss, L., Potente, M., Harder, D.R., Fleming, I., and Busse, R. 1999. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401: 493-497.
13. Fleming, I. 2001. Cytochrome P450 enzymes in vascular homeostasis. Circ. Res. 89: 753-762.
14. Gomez, G.A., Morisseau, C., Hammock, B.D., and Christianson, D.W. 2004. Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. Biochemistry 43: 4716-4723.
15. Hammock, B.D., Pinot, F., Beetham, J.K., Grant, D.F., Arand, M.E., and Oesch, F. 1994. Isolation of a putative hydroxyacyl enzyme intermediate of an epoxide hydrolase. Biochem. Biophys. Res. Commun. 198: 850-856.
16. Hammock, B.D., Grant, D.F., and Storms D.H. 1997. Epoxide hydrolases. In Comprehensive toxicology: Biotransformation (eds. I. Sipes et al.), pp. 283-305. Elsevier, New York.
17. Harder, D.R., Campbell, W.B., and Roman, R.J. 1995. Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J. Vasc. Res. 32: 79-92.
18. Hu, S. and Kim, H.S. 1993. Activation of K+ channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid. Eur. J. Pharmacol. 230: 215-221.
19. Imig, J.D., Zhao, X., Capdevila, J.H., Morisseau, C., and Hammock, B.D. 2002. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39: 690-694.
20. Jones, T.A., Zou, J.-Y., Cowan, S.W., and Kjeldgaard, M. 1991. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47: 110-119.
21. Kim, I.-H., Morisseau, C., Watanabe, T., and Hammock, B.D. 2004. Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J. Med. Chem. 47: 2110-2122.
22. Kraulis, P.J. 1991. Molscript: A program to produce both detailed and schematic plots of protein structures. J. Appl. Cryst. 24: 946-950.
23. Lacourciere, G.M. and Armstrong, R.N. 1993. The catalytic mechanism of microsomal epoxide hydrolase involves an ester intermediate. J. Am. Chem. Soc. 115: 10466-10467.
24. Laughlin, L.T., Tzeng, H.-F., Lin, S., and Armstrong, R.N. 1998. Mechanism of microsomal epoxide hydrolase. Semifunctional site-specific mutants affecting the alkylation half-reaction. Biochemistry 37: 2897-2904.
25. McElroy, N.R., Jurs, P.C., Morisseau, C., and Hammock, B.D. 2003. QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds. J. Med. Chem. 46: 1066-1080.
26. Merritt, E.A. and Murphy, M.E.P. 1994. Raster3D Version 2.0. A program for photorealistic molecular graphics. Acta. Crystallogr. D Biol. Crystallogr. 50: 869-873.
27. Morisseau, C., Du, G., Newman, J.W., and Hammock, B.D. 1998. Mechanism of mammalian soluble epoxide hydrolase inhibition by chalcone oxide derivatives. Arch. Biochem. Biophys. 356: 214-228.
28. Morisseau, C., Goodrow, M.H., Dowdy, D., Zheng, J., Greene, J.F., Sanborn, J.R., and Hammock, B.D. 1999. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc. Natl. Acad. Sci. 96: 8849-8854.
29. Morisseau, C., Goodrow, M.H., Newman, J.W., Wheelock, C.E., Dowdy, D.L., and Hammock, B.D. 2002. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem. Pharmacol. 63: 1599-1608.
30. Müller, F., Arand, M., Frank, H., Seidel, A., Hinz, W., Winkler, L., Hänel, K., Blée, E., Beetham, J.K., Hammock, B.D., et al.1997. Visualization of a covalent intermediate between microsomal epoxide hydrolase, but not cholesterol epoxide hydrolase, and their substrates. Eur. J. Biochem. 245: 490-496.
31. Nakagawa, Y., Wheelock, C.E., Morisseau, C., Goodrow, M.H., Hammock, B.G., and Hammock, B.D. 2000. 3-D QSAR analysis of inhibition of murine soluble epoxide hydrolase (MsEH) by benzoylureas, arylureas, and their analogues. Bioorg. Med. Chem. 8: 2663-2673.
32. Navaza, J. 1994. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 50: 157-163.
33. Otwinowski, Z. and Minor, W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276: 307-326.
34. Pflugrath, J.W. 1999. The finer things in X-ray diffraction data collection. Acta Crystallogr. D Biol. Crystallogr. 55: 1718-1725.
35. Pinot, F., Grant, D.F., Beetham, J.K., Parker, A.G., Borhan, B., Landt, S., Jones, A.D., and Hammock, B.D. 1995. Molecular and biochemical evidence for the involvement of the Asp-333-His-523 pair in the catalytic mechanism of soluble epoxide hydrolase. J. Biol. Chem. 270: 7968-7974.
36. Quilley, J. and McGiff, J.C. 2000. Is EDHF an epoxyeicosatrienoic acid? Trends Pharmocol. Sci. 21: 121-124.
37. Sinal, C.J., Miyata, M., Tohkin, M., Nagata, K., Bend, J.R., and Gonzalez, F.J. 2000. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J. Biol. Chem. 275: 40504-40510.
38. Wixtrom, R.N., Silva, M.H., and Hammock, B.D. 1988. Affinity purification of cytosolic epoxide hydrolase using derivatized epoxy-activated sepharose gels. Anal. Biochem. 169: 71-80.
39. Yamada, T., Morisseau, C., Maxwell, J.E., Argiriadi, M.A., Christianson, D.W. and Hammock, B.D. 2000. Biochemical evidence for the involvement of tyrosine in epoxide activation during the catalytic cycle of epoxide hydrolase. J. Biol. Chem. 275: 23082-23088.
40. Zeldin, D.C., Kobayashi, J., Falck, J.R., Winder, B.S., Hammock, B.D., Snapper, J.R., and Capdevila, J.H. 1993. Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J. Biol. Chem. 268: 6402-6407.